Cytodyn Inc (CYDY)

[ohm20]

Shorting 600 million market cap company with no approval and no revenue is a good things

It's like you don't know that catalysts drive biopharma share prices and Cytodyn has large upcoming catalysts.

Even sometimes after the fda approval the stock will wait for revenue results

What happens there is that the stock is highly oversold prior to FDA approval compared to what the actual revenue will be. AGRX being the most current example. With Cytodyn's long pipeline that shouldn't be a problem unless it shoots to $10+ that early. With BTD and continued advancement in the cancer indication even that price might not be a problem.